SweetWater Brewing Company, a subsidiary of Tilray Brands, has introduced Big Trip Double IPA, a 9% ABV extension of its Daytrip IPA that delivers bright citrus and tropical aromas. Crafted with Mosaic, Idaho 7, Sultana, Citra and El Dorado hops on a blend of 2-row, Pilsner and Wheat grains, the new release avoids the heavy maltiness typical of imperial styles. Available nationwide in 19.2-ounce cans and six-pack 12-ounce cans, Big Trip targets the Southeast craft market, where Double IPAs rank as the second most popular style and 80% of high-ABV beer sales occur in tall singles and six-packs. The rollout leverages SweetWater’s taproom footprint and retail partnerships across liquor stores, grocery chains and convenience outlets.

Tilray Medical has rebranded its Italian operations as Tilray Medical Italia, transitioning from its previous FL Group identity and aligning all European medical cannabis activities under a single global banner. Supported by a strategic partnership with Molteni Farmaceutici, the company now offers a portfolio of pharmaceutical-grade, Ministry of Health-authorized products—including five flower formulations ranging from 9% to 25% THC content and six oil preparations spanning THC-CBD ratios up to 25:25. Distribution through hospitals and pharmacies adheres to Italy’s regulated framework, while physician education initiatives and patient-access programs aim to drive adoption in one of Europe’s largest medical markets.

In its latest quarter, Tilray Brands reported a 36% increase in international cannabis revenues compared with the prior-year period, underscoring strong demand across Europe, Australia and Latin America. The growth reflects new supply agreements that shifted production toward Tilray’s GMP-certified facilities in Portugal and Germany, enabling launches in five additional markets. Tilray’s global platform now supports over 40 brands in more than 20 countries, with the international segment contributing an enlarged share of total cannabis sales and improving overall gross margins as regulatory complexities give way to scalable, cross-border operations.